| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Molecular Pharmacology, St. Jude Children's Research Hospital. Memphis, Tennessee 38101 [P. J. H., P. J. C., J. C. H., J. A. H.], and Rhône-Poulenc Rorer [M. C. B.] and Laboratoire Roger Bellon [A. M-B.], Neuilly-sur-Seine, France
The efficacy of the topoisomerase I inhibitor CPT-11 [7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin] has been evaluated against a panel of human tumor xenografts derived from adult and pediatric malignancies. Tumors included eight colon adenocarcinomas representing intrinsically chemorefractory malignancies, six lines derived from childhood rhabdomyosarcoma (three embryonal and three alveolar) representing a chemoresponsive histiotype, and sublines of rhabdomyosarcomas selected in vivo for resistance to vincristine, melphalan, and the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin (topotencan). CPT-11 was given by i.v. administration daily for 5 days each week for 2 weeks (one cycle of therapy) or on the same schedule with cycles repeated every 21 days. The maximum tolerated dose for a single cycle of treatment was 40 mg/kg/dose, and for 3 cycles the maximum tolerated dose was 10 mg/kg/dose. Treatment was started against advanced tumors. Against colon adenocarcinomas CPT-11 administered for one cycle at the maximum tolerated dose caused complete or partial regression (
50% reduction in tumor volume) in 5 of 8 lines. One cycle of CPT-11 therapy caused significant inhibition of tumor growth, without 50% regression, in 2 of 3 other colon adenocarcinomas. Rhabdomyosarcoma xenografts derived from untreated patients were highly responsive to CPT-11, which caused complete regression in 5 of 6 lines even at 20 or 10 mg/kg/dose. CPT-11 retained complete activity against rhabdomyosarcomas selected for resistance to vincristine and caused complete regressions in a line selected for resistance to melphalan that was also completely cross-resistant to topotecan. Of note was the observation that CPT-11 was as active against two xenografts selected for primary resistance to topotecan as it was against the respective parental tumors. Preliminary data indicate that CPT-11, like the topoisomerase I inhibitor topotecan, may have increased therapeutic efficacy when administered at a low dose for protracted periods (3 cycles). A comparison of the efficacy of CPT-11 with topotecan is presented.
1 Supported in part by USPHS Awards CA32613 and CA23099, Cancer Center Support CORE Grant CA21765, and the American Lebanese Syrian Associated Charities.
2 To whom requests for reprints should be addressed, at Department of Molecular Pharmacology, St. Jude Children's Research Hospital, 332 N. Lauderdale, Memphis, TN 38101.
Received 2/ 1/93. Accepted 4/12/93.
This article has been cited by other articles:
|
|
 |
|
  L. R. Bomgaars, M. Bernstein, M. Krailo, R. Kadota, S. Das, Z. Chen, P. C. Adamson, and S. M. Blaney Phase II Trial of Irinotecan in Children With Refractory Solid Tumors: A Children's Oncology Group Study J. Clin. Oncol., October 10, 2007; 25(29): 4622 - 4627. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Vassal, D. Couanet, E. Stockdale, A. Geoffray, B. Geoerger, D. Orbach, F. Pichon, J. C. Gentet, S. Picton, C. Bergeron, et al. Phase II Trial of Irinotecan in Children With Relapsed or Refractory Rhabdomyosarcoma: A Joint Study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group J. Clin. Oncol., February 1, 2007; 25(4): 356 - 361. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Hyatt, L. Tsurkan, M. Wierdl, C. C. Edwards, M. K. Danks, and P. M. Potter Intracellular inhibition of carboxylesterases by benzil: modulation of CPT-11 cytotoxicity. Mol. Cancer Ther., September 1, 2006; 5(9): 2281 - 2288. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. L. Furman, K. R. Crews, C. Billups, J. Wu, A. J. Gajjar, N. C. Daw, C. C. Patrick, C. Rodriguez-Galindo, C. F. Stewart, J. S. Dome, et al. Cefixime Allows Greater Dose Escalation of Oral Irinotecan: A Phase I Study in Pediatric Patients With Refractory Solid Tumors J. Clin. Oncol., February 1, 2006; 24(4): 563 - 570. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. Peterson, C. Tucker, E. Favours, P. J. Cheshire, J. Creech, C. A. Billups, R. Smykla, F. Y.F. Lee, and P. J. Houghton In vivo Evaluation of Ixabepilone (BMS247550), A Novel Epothilone B Derivative, against Pediatric Cancer Models Clin. Cancer Res., October 1, 2005; 11(19): 6950 - 6958. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. P. Breitfeld and W. H. Meyer Rhabdomyosarcoma: New Windows of Opportunity Oncologist, August 1, 2005; 10(7): 518 - 527. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. F. Stewart, M. Leggas, J. D. Schuetz, J. C. Panetta, P. J. Cheshire, J. Peterson, N. Daw, J. J. Jenkins III, R. Gilbertson, G. S. Germain, et al. Gefitinib Enhances the Antitumor Activity and Oral Bioavailability of Irinotecan in Mice Cancer Res., October 15, 2004; 64(20): 7491 - 7499. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Masi, A. Falcone, A. Di Paolo, G. Allegrini, R. Danesi, C. Barbara, S. Cupini, and Mario Del Tacca A Phase I and Pharmacokinetic Study of Irinotecan Given as a 7-Day Continuous Infusion in Metastatic Colorectal Cancer Patients Pretreated with 5-Fluorouracil or Raltitrexed Clin. Cancer Res., March 1, 2004; 10(5): 1657 - 1663. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Vassal, F. Doz, D. Frappaz, K. Imadalou, E. Sicard, A. Santos, J. O'Quigley, C. Germa, M.-L. Risse, D. Mignard, et al. A Phase I Study of Irinotecan As a 3-Week Schedule in Children With Refractory or Recurrent Solid Tumors J. Clin. Oncol., October 15, 2003; 21(20): 3844 - 3852. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ray and A. Almasan Apoptosis Induction in Prostate Cancer Cells and Xenografts by Combined Treatment with Apo2 Ligand/Tumor Necrosis Factor-related Apoptosis-inducing Ligand and CPT-11 Cancer Res., August 1, 2003; 63(15): 4713 - 4723. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Bodurka, C. Levenback, J. K. Wolf, J. Gano, J. T. Wharton, J. J. Kavanagh, and D. M. Gershenson Phase II Trial of Irinotecan in Patients With Metastatic Epithelial Ovarian Cancer or Peritoneal Cancer J. Clin. Oncol., January 15, 2003; 21(2): 291 - 297. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Houghton, P. C. Adamson, S. Blaney, H. A. Fine, R. Gorlick, M. Haber, L. Helman, S. Hirschfeld, M. G. Hollingshead, M. A. Israel, et al. Testing of New Agents in Childhood Cancer Preclinical Models: Meeting Summary Clin. Cancer Res., December 1, 2002; 8(12): 3646 - 3657. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Guichard, A. Montazeri, E. Chatelut, I. Hennebelle, R. Bugat, and P. Canal Schedule-dependent Activity of Topotecan in OVCAR-3 Ovarian Carcinoma Xenograft: Pharmacokinetic and Pharmacodynamic Evaluation Clin. Cancer Res., October 1, 2001; 7(10): 3222 - 3228. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Wadkins, C. L. Morton, J. K. Weeks, L. Oliver, M. Wierdl, M. K. Danks, and P. M. Potter Structural Constraints Affect the Metabolism of 7-Ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) by Carboxylesterases Mol. Pharmacol., August 1, 2001; 60(2): 355 - 362. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Wierdl, C. L. Morton, J. K. Weeks, M. K. Danks, L. C. Harris, and P. M. Potter Sensitization of Human Tumor Cells to CPT-11 via Adenoviral-mediated Delivery of a Rabbit Liver Carboxylesterase Cancer Res., July 1, 2001; 61(13): 5078 - 5082. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Vanhoefer, A. Harstrick, W. Achterrath, S. Cao, S. Seeber, and Y. M. Rustum Irinotecan in the Treatment of Colorectal Cancer: Clinical Overview J. Clin. Oncol., March 1, 2001; 19(5): 1501 - 1518. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Houghton, C. F. Stewart, P. J. Cheshire, L. B. Richmond, M. N. Kirstein, C. A. Poquette, M. Tan, H. S. Friedman, and T. P. Brent Antitumor Activity of Temozolomide Combined with Irinotecan Is Partly Independent of O6-Methylguanine-DNA Methyltransferase and Mismatch Repair Phenotypes in Xenograft Models Clin. Cancer Res., October 1, 2000; 6(10): 4110 - 4118. [Abstract] [Full Text]
|
|
|
|
|
|
R. Khanna, C. L. Morton, M. K. Danks, and P. M. Potter Proficient Metabolism of Irinotecan by a Human Intestinal Carboxylesterase Cancer Res., September 1, 2000; 60(17): 4725 - 4728. [Abstract] [Full Text]
|
|
|
|
|
|
C. L. Morton, M. Wierdl, L. Oliver, M. K. Ma, M. K. Danks, C. F. Stewart, J. L. Eiseman, and P. M. Potter Activation of CPT-11 in Mice: Identification and Analysis of a Highly Effective Plasma Esterase Cancer Res., August 1, 2000; 60(15): 4206 - 4210. [Abstract] [Full Text]
|
|
|
|
|
|
J. C. Cusack Jr., R. Liu, and A. S. Baldwin Jr. Inducible Chemoresistance to 7-Ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) in Colorectal Cancer Cells and a Xenograft Model Is Overcome by Inhibition of Nuclear Factor-{{kappa}}B Activation Cancer Res., May 1, 2000; 60(9): 2323 - 2330. [Abstract] [Full Text]
|
|
|
|
|
|
M. K. Ma, W. C. Zamboni, K. M. Radomski, W. L. Furman, V. M. Santana, P. J. Houghton, S. K. Hanna, A. K. Smith, and C. F. Stewart Pharmacokinetics of Irinotecan and Its Metabolites SN-38 and APC in Children with Recurrent Solid Tumors after Protracted Low-Dose Irinotecan Clin. Cancer Res., March 1, 2000; 6(3): 813 - 819. [Abstract] [Full Text]
|
|
|
|
|
|
D. S. Middlemas, C. F. Stewart, M. N Kirstein, C. Poquette, H. S. Friedman, P. J. Houghton, and T. P. Brent Biochemical Correlates of Temozolomide Sensitivity in Pediatric Solid Tumor Xenograft Models Clin. Cancer Res., March 1, 2000; 6(3): 998 - 1007. [Abstract] [Full Text]
|
|
|
|
|
|
B. Gliniak and T. Le Tumor Necrosis Factor-related Apoptosis-inducing Ligand's Antitumor Activity in Vivo Is Enhanced by the Chemotherapeutic Agent CPT-11 Cancer Res., December 1, 1999; 59(24): 6153 - 6158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. L. Furman, C. F. Stewart, C. A. Poquette, C. B. Pratt, V. M. Santana, W. C. Zamboni, L. C. Bowman, M. K. Ma, F. A. Hoffer, W. H. Meyer, et al. Direct Translation of a Protracted Irinotecan Schedule From a Xenograft Model to a Phase I Trial in Children J. Clin. Oncol., June 1, 1999; 17(6): 1815 - 1815. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. O'Leary, R. L. Shapiro, C. J. Ren, N. Chuang, H. W. Cohen, and M. Potmesil Antiangiogenic Effects of Camptothecin Analogues 9-Amino-20(S)-camptothecin, Topotecan, and CPT-11 Studied in the Mouse Cornea Model Clin. Cancer Res., January 1, 1999; 5(1): 181 - 187. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Knab, J. Fertala, and M.-A. Bjornsti A Camptothecin-resistant DNA Topoisomerase I Mutant Exhibits Altered Sensitivities to Other DNA Topoisomerase Poisons J. Biol. Chem., March 17, 1995; 270(11): 6141 - 6148. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
